CN118667024A - 新型拮抗性抗tnfr2抗体分子 - Google Patents

新型拮抗性抗tnfr2抗体分子 Download PDF

Info

Publication number
CN118667024A
CN118667024A CN202411004493.6A CN202411004493A CN118667024A CN 118667024 A CN118667024 A CN 118667024A CN 202411004493 A CN202411004493 A CN 202411004493A CN 118667024 A CN118667024 A CN 118667024A
Authority
CN
China
Prior art keywords
seq
antibody molecule
antibody
tnfr2
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411004493.6A
Other languages
English (en)
Chinese (zh)
Inventor
B·弗伦德修斯
英格丽德·泰格
L·玛藤松
P·霍尔姆奎斯特
M·塞姆里奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioinvent International AB
Original Assignee
Bioinvent International AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioinvent International AB filed Critical Bioinvent International AB
Publication of CN118667024A publication Critical patent/CN118667024A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202411004493.6A 2018-11-01 2019-11-01 新型拮抗性抗tnfr2抗体分子 Pending CN118667024A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP18203993.3 2018-11-01
EP18203993 2018-11-01
PCT/EP2019/080004 WO2020089474A1 (en) 2018-11-01 2019-11-01 Novel antagonistic anti tnfr2 antibody molecules
CN201980071097.6A CN112955469B (zh) 2018-11-01 2019-11-01 新型拮抗性抗tnfr2抗体分子

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980071097.6A Division CN112955469B (zh) 2018-11-01 2019-11-01 新型拮抗性抗tnfr2抗体分子

Publications (1)

Publication Number Publication Date
CN118667024A true CN118667024A (zh) 2024-09-20

Family

ID=64109794

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202411004493.6A Pending CN118667024A (zh) 2018-11-01 2019-11-01 新型拮抗性抗tnfr2抗体分子
CN201980071097.6A Active CN112955469B (zh) 2018-11-01 2019-11-01 新型拮抗性抗tnfr2抗体分子
CN202411004492.1A Pending CN118702818A (zh) 2018-11-01 2019-11-01 新型拮抗性抗tnfr2抗体分子

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201980071097.6A Active CN112955469B (zh) 2018-11-01 2019-11-01 新型拮抗性抗tnfr2抗体分子
CN202411004492.1A Pending CN118702818A (zh) 2018-11-01 2019-11-01 新型拮抗性抗tnfr2抗体分子

Country Status (11)

Country Link
US (2) US12441805B2 (https=)
EP (1) EP3873936A1 (https=)
JP (2) JP7646542B2 (https=)
KR (1) KR20210087029A (https=)
CN (3) CN118667024A (https=)
AU (1) AU2019372184A1 (https=)
BR (1) BR112021007995A2 (https=)
CA (1) CA3117864A1 (https=)
IL (1) IL282715A (https=)
MX (1) MX2021005150A (https=)
WO (1) WO2020089474A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119591711A (zh) * 2024-11-12 2025-03-11 澳门大学 一种抑制性tnfr2单域抗体及其应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI878554B (zh) 2020-06-12 2025-04-01 大陸商南京維立志博生物科技股份有限公司 結合ｔｎｆｒ２的抗體及其用途
US20240043551A1 (en) * 2020-12-11 2024-02-08 Adlai Nortye Biopharma Co., Ltd. Anti-tnfr2 antibody and application thereof
TW202235434A (zh) * 2020-12-31 2022-09-16 美商諾瓦拉克生物醫療有限公司 針對tnfr2之抗體及其用途
CN117425675A (zh) * 2020-12-31 2024-01-19 新石生物制药有限公司 Tnfr2抗体及其用途
EP4286411A4 (en) * 2021-01-29 2025-06-25 Shandong Simcere Biopharmaceutical Co., Ltd. Humanized antibody against tnfr2 and use thereof
EP4067381A1 (en) 2021-04-01 2022-10-05 Julius-Maximilians-Universität Würzburg Novel tnfr2 binding molecules
CN116333123A (zh) * 2021-12-22 2023-06-27 宝船生物医药科技(上海)有限公司 抗tnfr2抗体及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101001872A (zh) * 2004-04-16 2007-07-18 宏观基因有限公司 FcγRIIB－特异性抗体及其使用方法
CN1997667A (zh) * 2004-05-10 2007-07-11 宏观基因有限公司 人源化FcγRⅡB特异性抗体及其使用方法
EP2371390A3 (en) 2004-10-08 2013-03-13 Domantis Limited Antagonists and methods of use therefor
TWI687439B (zh) 2011-06-30 2020-03-11 中外製藥股份有限公司 異源二聚化多胜肽
EP3936137A1 (en) 2013-02-07 2022-01-12 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells
RU2696312C2 (ru) * 2014-07-16 2019-08-01 Трансген Са Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек
EP3973980A1 (en) * 2015-03-31 2022-03-30 F. Hoffmann-La Roche AG Antigen binding molecules comprising a trimeric tnf family ligand
CN115043943A (zh) * 2015-05-15 2022-09-13 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
US20190135929A1 (en) 2015-08-28 2019-05-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
AU2016317915B2 (en) * 2015-09-01 2021-02-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
CA3004830A1 (en) * 2015-11-11 2017-05-18 Opi Vi- Ip Holdco Llc Composition and methods for anti-tnfr2 antibodies
US11859002B2 (en) 2016-05-13 2024-01-02 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor 2 antibodies
EP3475301B1 (en) 2016-06-22 2023-01-04 Université Paris-Est Créteil Val de Marne Prevention or treatment of hematologic malignancy relapse using a tnfr2 antagonist

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119591711A (zh) * 2024-11-12 2025-03-11 澳门大学 一种抑制性tnfr2单域抗体及其应用

Also Published As

Publication number Publication date
US20220073634A1 (en) 2022-03-10
US20250388690A1 (en) 2025-12-25
JP2022512905A (ja) 2022-02-07
JP7646542B2 (ja) 2025-03-17
WO2020089474A1 (en) 2020-05-07
EP3873936A1 (en) 2021-09-08
US12441805B2 (en) 2025-10-14
WO2020089474A8 (en) 2021-06-24
BR112021007995A2 (pt) 2021-08-10
KR20210087029A (ko) 2021-07-09
CN112955469B (zh) 2024-08-06
CA3117864A1 (en) 2020-05-07
IL282715A (en) 2021-06-30
CN112955469A (zh) 2021-06-11
AU2019372184A1 (en) 2021-05-27
CN118702818A (zh) 2024-09-27
MX2021005150A (es) 2021-07-15
JP2025022888A (ja) 2025-02-14

Similar Documents

Publication Publication Date Title
US20250066492A1 (en) Agonistic anti tnfr2 antibody molecules
CN112955469B (zh) 新型拮抗性抗tnfr2抗体分子
CN113301919B (zh) 激活免疫细胞的双特异性抗体
US20200407446A1 (en) Bispecific antibody for icos and pd-l1
JP2019515661A (ja) Ｂｃｍａ結合分子及びその使用方法
JP2025157343A (ja) 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用
CN111683969A (zh) 抗体的新型组合和用途
CN121102465A (zh) 用于治疗特定患者的癌症的抗体组合
CA3259108A1 (en) Attenuated Anti-PD1-IL2 Immunoconjugates and Their Uses
RU2829587C2 (ru) Новые молекулы антагонистических анти-tnfr2-антител
HK40109442A (zh) 新型拮抗性抗tnfr2抗体分子
HK40110145A (zh) 新型拮抗性抗tnfr2抗体分子
HK40050308A (en) Novel antagonistic anti tnfr2 antibody molecules
HK40050308B (zh) 新型拮抗性抗tnfr2抗体分子
HK40128816A (zh) 新颖激动性抗tnfr2抗体分子
HK40129120A (zh) 新颖激动性抗tnfr2抗体分子
RU2840049C9 (ru) Новые молекулы агонистических анти-tnfr2 антител
RU2840049C2 (ru) Новые молекулы агонистических анти-tnfr2 антител
RU2800035C2 (ru) Новая комбинация антител и ее применение
HK40053328B (zh) 新颖激动性抗tnfr2抗体分子

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40109442

Country of ref document: HK